Liver Fibrosis Market Expected to Experience Significant Growth with New Treatments by 2034 The liver fibrosis market is forecasted to grow significantly at a CAGR of 24% from 2025 to 2034, driven by new therapies and rising patient prevalence.

Liver Fibrosis Market Expected to Experience Significant Growth with New Treatments by 2034 #None #MASH #liver_fibrosis #REZDIFFRA

Early returns on my #resmetirom #rezdiffra #MASH patients at 1 year. So far 7/8 patients reasessed with LSM have a 30% or greater reduction. Hopefully we start getting some real world data to complement the open label trial.
#liversky

I am a big #ELF fan esp for 2ry screening assessment in #MASH & identification of #rezdiffra pts.
Major issue with it is that @SiemensHealth reports reflect risk propensity not fibrosis stage.
So…I scurried the literature & made my own!

Fight me! #livertwitter

At our shop:

VCTE at baseline and annually cap 280+ and LSM 9-15 with ELF>9.8 good for #rezdiffra
cT1 at baseline and annually when covered
If discordant—> bx
F/u annually with same
LSM < by 20%=improved. Less=stable
cT1 drop > 80 ms=improved (nice work by @AlkhouriNaim)

Good to see a #rezdiffra formulary patch in #EPIC on #WorldLiverDay2024 #WorldLiverDay2024 #livertwitter

In what may be a case of saving the best for last (out of a fantastic @CLDFoundation #liverconnect meeting), @NoureddinMD with a tour de force covering #MASH from NITs to how to select appropriate #rezdiffra patients to measured optimism about the future #livertwitter

#livertwitter would you consider using #rezdiffra in a person with F3 & strong metabolic risk factors who also meets definition of 🍷🥯 MetALD?

#livertwitter how do you plan to assess response to rx with #rezdiffra ?

@PerspectumGroup @MadrigalPharma @PerspectumGroup @SiemensHealth

Nothing like a medication approval for non cirrhotic #MASH with fibrosis to stimulate discussion and education about NITs. Ultimately patients benefit and we all learn @AlkhouriNaim @NoureddinMD @DrHuangDQ @DrLoomba @NASH_and_coffee #rezdiffra #livertwitter

FDA approves first drug for common form of liver inflamma... The US Food and Drug Administration has approved the firs...

Thank you ⁦@jechristensen⁩ ⁦@WayneEskridge1⁩ and ⁦@CNN⁩ for raising awareness about steatotic liver disease and treatment options w #rezdiffra #resmetirom #livertwitter ⁦@FattyLiverA⁩ ⁦@GlobalLiver⁩ ⁦@KnowledgeNash⁩ https://dir.lat/iWDRK7

Summary of DDI management with #rezdiffra #resmetirom

✅ Rosuvastatin and simvastatin: no more than 20 mg/d
✅ Pravastatin and atorvastatin: no more than 40 mg/d
✅ reduce by 20 mg with clopidrogel
🛑 don’t use with Gemfibrozil and cyclosporine

#livertwitter

Don’t see an official wholesaler acquisition cost (WAC) for #rezdiffra yet but @icer_review paper-> price range that would achieve incremental cost-effectiveness ratios between $100,000 and $150,000 per QALY gained, was $39,600 to $50,100 for...

⁦@OHIOLIVER⁩ welcomes the news of the first ever approval of a drug in the steatotic liver disease space: ⁦⁦@MadrigalPharma⁩ #rezdiffra
Great news for many Ohioans and an estimated 8 million Americans...

Link to the full #rezdiffra label below

www.madrigalpharma.com/wp-content/uploads/2024/...
#livertwitter

Perhaps the most important part of the #rezdiffra label is that it is not prescriptive as to how fibrosis stage is determined by the clinician.
Label clearly states dont give in CPT B/C
#livertwitter

#rezdiffra more label highlights
✅take w or w/o food
✅comes in 60, 80 and 100 mg tabs
✅reduce by 20 mg from intended wt based dose if con med is CYP2C8 mod inh. (Clopidrogel) and not recommended with gemfibrozil
✅give lowest doses of statins if con med
#livertwitter

#rezdiffra label highlights:
✅F2-F3 non cirrhosis
✅wt based 80 mg QD for <100 kg
100 mg QD for >100 kg
✅monitor for GB disease and ✋if cholecystitis
✅potential DDIs w/ CYP2C8 inh. (gemfinrozil, clopidrogel) so adjust and monitor
✅don’t use with cyclosporine #livertwitter

#resmetirom is #rezdiffra the first ever @US_FDA approval in the steatotic liver disease space #livertwitter